These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8309069)

  • 1. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. I. Results against methicillin-resistant Staphylococcus aureus].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1993 Nov; 46(11):939-45. PubMed ID: 8309069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. II. Results against gram-negative rods].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1993 Nov; 46(11):946-52. PubMed ID: 8309070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro].
    Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K
    Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bacteriological evaluations of combination effects with cefotiam and other antimicrobial agents against methicillin-resistant Staphylococcus aureus. I. Synergistic actions of cefotiam with imipenem and vancomycin].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R
    Jpn J Antibiot; 1993 Feb; 46(2):115-22. PubMed ID: 8331771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria].
    Higurashi Y; Okuzumi K; Yoneyama A; Nakahara K
    Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)].
    Hatano K; Yokota Y; Hanaki H; Sunakawa K
    Kansenshogaku Zasshi; 2006 May; 80(3):243-50. PubMed ID: 16780131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro antibacterial activity of vancomycin in combination with panipenem against carbapenem-resistant MRSA].
    Sato S; Miura T; Kudo Y; Kudo E; Saitoh Y; Kimpara I; Tsujino M; Kudo H
    Jpn J Antibiot; 1998 Jul; 51(7):488-93. PubMed ID: 9755432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus].
    Fukuoka T; Domon H; Kakuta M; Ishii C; Hirasawa A; Utsui Y; Ohya S; Yasuda H
    Jpn J Antibiot; 1997 Apr; 50(4):411-9. PubMed ID: 9192249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro synergism of two-drug combinations among cefamandole, flomoxef and imipenem against MRSA].
    Inoue M; Sakurai N; Matsui H; Tsunoda M; Okubo T
    Jpn J Antibiot; 1990 Feb; 43(2):233-8. PubMed ID: 2362351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination effect of arbekacin and cefepime on mixed culture of MRSA and P. aeruginosa].
    Araake M; Hara T; Miyata A; Tani M; Ogawa H
    Jpn J Antibiot; 2001 Feb; 54(2):69-78. PubMed ID: 11338680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibacterial activity of imipenem in combination with ampicillin against methicillin-resistant strains of Staphylococcus aureus].
    Saionji K; Shitara M; Miyake N; Inoue K; Kobayashi I
    Jpn J Antibiot; 1990 Oct; 43(10):1685-97. PubMed ID: 2086811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.
    Rochon-Edouard S; Pestel-Caron M; Lemeland JF; Caron F
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3055-60. PubMed ID: 11036022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical studies on vancomycin in the treatment of MRSA infection].
    Shimizu K; Orizu M; Kanno H; Kitamura S; Konishi T; Soma K; Nishitani H; Noguchi Y; Hasegawa S; Hasegawa H; Wada K
    Jpn J Antibiot; 1996 Aug; 49(8):782-99. PubMed ID: 9053533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacteriological activities of arbekacin and vancomycin against strains of MRSA].
    Ishii T; Takayama Y; Takase Y; Orikasa Y
    Jpn J Antibiot; 1994 Jun; 47(6):647-54. PubMed ID: 8072173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA].
    Sato S; Miura T; Kudo E; Kudo Y; Saitoh Y; Kimpara I; Tsujino M; Kudo H
    Jpn J Antibiot; 1997 Aug; 50(8):711-6. PubMed ID: 9339397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Basic studies on combination effects of arbekacin and beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus].
    Watanabe T; Sobu K; Takase Y; Kawabata T; Kanno M; Yoshida T
    Jpn J Antibiot; 1994 Jun; 47(6):701-9. PubMed ID: 8072178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination effect of vancomycin and cefpirome against methicillin-resistant Staphylococcus aureus in vitro--antimicrobial activities in postantibiotic phase].
    Hasegawa H; Kanai A; Otoguro K; Shimizu K
    Kansenshogaku Zasshi; 1996 Feb; 70(2):151-60. PubMed ID: 8851387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.
    Miranda-Novales G; Leaños-Miranda BE; Vilchis-Pérez M; Solórzano-Santos F
    Ann Clin Microbiol Antimicrob; 2006 Oct; 5():25. PubMed ID: 17034644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.